Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120  by Kirchherr, Jennifer L. et al.
Virology 409 (2011) 163–174
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roIdentiﬁcation of amino acid substitutions associated with neutralization phenotype
in the human immunodeﬁciency virus type-1 subtype C gp120
Jennifer L. Kirchherr a,b, Jennifer Hamilton a,b, Xiaozhi Lu a,b, S. Gnanakaran d, Mark Muldoon e,
Marcus Daniels d, Webster Kasongo f, Victor Chalwe f, Chanda Mulenga f, Lawrence Mwananyanda f,
Rosemary M. Musonda f, Xing Yuan c, David C. Monteﬁori c, Bette T. Korber d,g,
Barton F. Haynes a,b, Feng Gao a,b,⁎
a Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
b Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
c Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
d Los Alamos National Laboratory, Los Alamos, NM 87545, USA
e School of Mathematics, University of Manchester, Manchester, M13 9PL, UK
f The Tropical Disease Research Centre, PO Box 71769 Ndola, Zambia
g Santa Fe Institute, Santa Fe, NM 87501, USA⁎ Corresponding author. 3072B MSRB II, DUMC 1030
Human Vaccine Institute, Duke University Medical Cen
Fax: +1 919 681 8992.
E-mail address: fgao@duke.edu (F. Gao).
0042-6822/$ – see front matter © 2010 Elsevier Inc. Al
doi:10.1016/j.virol.2010.09.031a b s t r a c ta r t i c l e i n f oArticle history:
Received 13 July 2010
Returned to author for revision
22 August 2010
Accepted 27 September 2010
Available online 30 October 2010
Keywords:
HIV-1
Envelope
Genetic variation
Neutralization
SignatureNeutralizing antibodies (Nabs) are thought to play an important role in prevention and control of HIV-1
infection and should be targeted by an AIDS vaccine. It is critical to understand how HIV-1 induces Nabs by
analyzing viral sequences in both tested viruses and sera. Neutralization susceptibility to antibodies in
autologous and heterologous plasma was determined for multiple Envs (3–6) from each of 15 subtype-C-
infected individuals. Heterologous neutralization was divided into two distinct groups: plasma with strong,
cross-reactive neutralization (n=9) and plasmawith weak neutralization (n=6). Plasmawith cross-reactive
heterologous Nabs also more potently neutralized contemporaneous autologous viruses. Analysis of Env
sequences in plasma from both groups revealed a three-amino-acid substitution pattern in the V4 region that
was associated with greater neutralization potency and breadth. Identiﬁcation of such potential
neutralization signatures may have important implications for the development of HIV-1 vaccines capable
of inducing Nabs to subtype C HIV-1.20, 106 Research Drive, Duke
ter, Durham, NC 27710, USA.
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The ability to elicit cross-reactive neutralizing antibodies (Nabs) is
an important goal for HIV-1 vaccines (Burton et al., 2004; Haynes and
Monteﬁori, 2006). HIV-1 has nine genetically related lineages
(subtypes A–K), and at a minimum, at least one clade should be
effectively targeted in an HIV vaccine for the vaccine to be useful in a
part of the world where a single subtype dominates the epidemic
(Korber and Gnanakaran, 2009; Korber et al., 2009). Nabs capable of
targeting subtype C variants of the virus would be particularly useful,
since subtype C accounts for approximately 50% of all HIV-1 infections
world-wide (Hemelaar et al., 2006). In addition, the HIV epidemic in
large regions of Southern Africa and India is almost completely
dominated by subtype C infections; hence in this study, we focus on
subtype C antibody responses in natural infection. Efforts to generatecross-reactive Nabs have had limited success, and novel approaches
are urgently needed (Burton et al., 2004; Desrosiers, 2004). Cross-
reactive neutralizing activity that is seen with a subset of human
monoclonal Abs (Binley et al., 2004; Lin and Nara, 2007; Moore et al.,
1994; Trkola et al., 1995; Wu et al., 2010; Zwick et al., 2001) and
serum samples from HIV-1-infected individuals (Binley et al., 2008;
Dhillon et al., 2007; Li et al., 2007; Sather et al., 2009; Shen et al., 2009;
Stamatatos et al., 2009) is evidence that improvements in immunogen
design may be possible.
Insights into how to make such improvements are being sought by
studying autologous and heterologous Nabs in HIV-1-positive serum
samples. Recent results indicate that epitopes in and around the CD4
binding site of gp120 comprise key targets for broadly neutralizing
HIV-1-positive sera and that other key targets that play a substantial
role remain to be identiﬁed (Binley et al., 2008; Dhillon et al., 2007; Li
et al., 2007; Wu et al., 2010; Zhou et al., 2010). Studies of autologous
virus neutralization have shown that the response targets multiple
regions of gp120, most notably epitopes in V1/V2 (Rong et al., 2009)
and epitopes that require an interaction between C3 and V4 (Moore
et al., 2008, 2009; Rademeyer et al., 2007; Rong et al., 2009). A recent
Table 1
Summary of SGAs and functional env genes from HIV-1-infected individuals.
ID Gender Age Viral load Subtype No. of
SGAs
No. of
functional
env genes
Functional
env genes
(%)
ZM373 M 25 44,800 C 5 4 80
ZM375 F 31 52,800 C 10 8 80
ZM376 F 30 105,600 C 15 13 87
ZM377 M 41 248,800 C 16 15 94
ZM378 F 36 67,200 C 13 11 85
ZM379 M 35 97,600 C 14 11 79
ZM380 M 37 268,800 A/C 10 10 100
ZM381 F 36 487,200 C 13 12 92
ZM382 M 39 557,600 C 10 10 100
ZM383 F 31 20,240 C 10 5 50
ZM384 M 41 15,440 C 11 10 91
ZM387 M 30 1,120 G/J 9 9 100
ZM388 F 28 21,360 C 11 6 55
ZM389 M 33 1,520,000 C 10 10 100
ZM393 F 21 b384 C 11 2 18
ZM394 F 30 197,600 C 19 12 63
ZM395 F 22 776,800 C 21 20 95
ZM399 M 36 68,240 C 14 14 100
ZM400 M 35 103,200 C 18 15 83
ZM401 M 34 84,000 C 11 9 82
ZM402 F 37 3,920 C 9 6 67
ZM403 F 45 48,080 C 11 10 91
ZM405 F 36 13,920 C 12 9 75
ZM406 M 27 104,000 C 10 10 100
ZM407 M 38 283,200 D 11 9 82
ZM408 F 26 42,400 C 10 8 80
ZM410 M 42 143,200 C 11 6 55
ZM411 F 41 61,600 C 14 6 43
ZM412 F 30 260,000 C 10 7 70
ZM413 F 34 155,200 C 16 14 88
ZM414 F 25 213,600 C 22 14 64
ZM415 M 38 64,720 C 21 18 86
ZM416 M 45 80,800 C 23 23 100
ZM417 M 32 96,000 C 9 9 100
ZM418 F 21 532,000 C 10 8 80
ZM419 F 33 433,600 C 10 1 10
ZM420 F 24 286,400 C 14 13 93
Total 474 377 80
164 J.L. Kirchherr et al. / Virology 409 (2011) 163–174study identiﬁed 19 signatures in gp120 and 14 signatures in gp41
associated with neutralization susceptibility of a multi-subtype panel
of viruses (Kulkarni et al., 2009).Walker et al. have recently found two
mAbs that bind to conformation determinants of HIV-1 Env and
broadly neutralize about two-thirds of viruses tested (Walker et al.,
2009).
Previous studies of the autologous and heterologous Nab
responses in HIV-1 infection have utilized one or a limited number
of representative env genes from each individual to characterize
neutralization susceptibility (Cham et al., 2006; Derdeyn et al., 2004;
Wei et al., 2003; Zhang et al., 2007). Since env is highly variable in
chronic HIV-1 infection (CHI) and because minor sequence changes
can affect the biological function and antigenicity of the envelope
glycoproteins (Cordonnier et al., 1989; Kalia et al., 2005; LaBranche
et al., 1995; Morris et al., 1994; Shimizu et al., 1999; Shioda et al.,
1994), the study of a single env gene from each infected individual
provides only a minimal representation of viral populations in vivo.
Thus, depending on the design of the study, key information about
neutralization epitopes may be missed under these conditions.
Another limitation of previous studies is the reliance on a
traditional bulk PCR methodology for Env cloning (Cham et al.,
2006; Derdeyn et al., 2004; Palmer et al., 2005;Wei et al., 2003; Zhang
et al., 2007). Viral sequences from the quasispecies population
obtained by bulk PCR can result in artiﬁcial recombination and
resampling as well as in nucleoside misincorporation by low-ﬁdelity
Taq polymerase (Fang et al., 1998; Liu et al., 1996; Salazar-Gonzalez
et al., 2008). The single-genome ampliﬁcation (SGA) methodology
makes it possible to obtain bona ﬁde viral genomes from the infected
individual (Keele et al., 2008; Kirchherr et al., 2007; Palmer et al.,
2005; Salazar-Gonzalez et al., 2008). Because viral sequences obtained
by SGA more accurately reﬂect what is present in vivo, they can be
used to better characterize viral gene functions.
The study of multiple env genes in chronic infection in autologous
and heterologous neutralization assays enabled us to explore the
question of whether there are common neutralization signatures that
associate with cross-reactive Nab responses among clade C viral
sequences.We have utilized SGA and a novel promoter PCRmethod to
express functional Envs in a high-throughput format (Kirchherr et al.,
2007). Multiple env genes from each of 37 HIV-1-infected individuals
were obtained and characterized with respect to their infectivity and
their susceptibility to neutralization by autologous and heterologous
plasma samples. After scanning the full Env for potential signature
sites, we found potential signature amino acids in the fourth variable
region (V4) of gp120 that were associated with cross-reactive Nab
responses in subtype C HIV-1-infected individuals; this region has
been shown to be critical for NAb susceptibility in the C subtype
(Moore et al., 2008).
Results
Genetic analysis of full-length env genes
Plasma samples were collected from 50 CHI individuals in Ndola,
Zambia, in 2005. A total of 474 complete env geneswere obtained from
37 of 50 subjects by SGA. Negative PCR results for the remaining 13
subjects were due to either low or undetectable plasma viral loads. An
average of thirteen env SGAs (range 5–23) were sequenced from each
of the 37 PCR-positive subjects (Table 1). Phylogenetic analysis
showed that the majority of subjects (n=34) were infected with
HIV-1 subtype C (Fig. 1). Three others were infected with either
subtype D, an A/C recombinant (subtype C in themost central region),
or a G/J recombinant.
Identical or closely related env sequences were identiﬁed in 13 of
37 (35%) of subjects (Table 2), suggesting frequent clonal expansion
of minority viral populations in the HIV-1-infected individuals. In
these subjects, clonally expanded Envs comprised 9–38% of thesampled env population. Clonal expansion sequences formed a tight
cluster with zero or very short branch lengths in the phylogenetic
trees (Fig. 2); this tight clustering was supported by high bootstrap
values (N85%). Nine subjects had one clonally expanded env variant
(Fig. 2A–I), whereas another four subjects (ZM377, ZM405, ZM414,
and ZM415) had two independent clonally expanded populations
(Fig. 2J–M). Clonally expanded variants in two subjects (ZM402 and
ZM405) formed new lineages (Fig. 2E and K). Sequences closely
related to, but beginning to diverge from the clonally expanded
variants, were observed in four subjects (ZM377, ZM401, ZM414, and
ZM415) (Fig. 2D, J, L, and M). Recombinant env sequences were also
detected between clonally expanded viruses and other viruses in
ZM394 (Fig. 2I). These latter recombinants contributed to a
substantial increase in diversity of the viral population in the subject.
When recombinant sequences were excluded from the phylogenetic
tree, the clonally expanded viruses represented an emergence of a
new viral lineage in the subject (Fig. 2I).Functional analysis of the env quasispecies in infected individuals
A pPCR method that adds a CMV promoter to SGA amplicons was
used for high-throughput functional screening of multiple env genes
from each infected individual (Kirchherr et al., 2007). Env-pseudo-
typed viruses were generated by cotransfecting 293T cells with pPCR
products and an Env-defective backbone plasmid (SG3Δenv).
Fig. 1. Phylogenetic tree analysis of newly characterized full-length env gene sequences. An unrooted phylogenetic tree was constructed with complete env gene sequences using the
neighbor-joining method and the Kimura two-parameter model. The branch lengths are drawn to scale (the scale bar represents 0.02 nucleotide substitutions per site).
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474 Envs examined, 377 (80%) were found to be functional (Table 1).
All env genes were functional in eight subjects, whereas in a few
subjects, only a small fraction of env genes were functional (10% and
18% for ZM419 and ZM393, respectively). In three individuals
(ZM373, ZM380, and ZM382), all Env-pseudotyped viruses were
highly infectious and differed in infectivity by only a few fold (Fig. 3).
Notably, infectivity of Env-pseudotyped viruses from most other
individuals was highly variable (1–2 log differences in luciferase
activity).
Recombinant genes were found in 11 env sequences from 6
individuals infected with two lineage viruses. Examination of their
functionality showed that 8 (73%) were biologically functional while
the other 3 were not. ZM420.9 was not functional due to a reading
frame shift caused by one nucleotide insertion. The result suggested
that while some recombinants might gain biological advantages,
others might be lethal and result in nonfunctional genes. For example,
in ZM394, the recombinant viruses between the clonal expansion
viruses and other viruses resulted in different levels of infectivity,
ranging from nonfunctional to highly infectious (Figs. 2I and 3).
However, recombinant sequences were not particularly enriched for
inactive viruses relative to non-recombinant (Fisher's Exact Test,
p=0.4).
Given the range of variability in Env function, it was of interest to
determine whether the level of Env infectivity in pseudovirus assays
was associated with either protein expression levels or with plasma
viral RNA load. As shown in Fig. 4, a trend towards a positive
correlation was seen between pseudovirus infectivity and viral load
(p=0.05). Protein expression in transfected 293T cells was quantiﬁed
by Western blot for multiple env SGAs from three subjects (ZM400,
ZM413, and ZM414) whose Env clones demonstrated a substantial
range in infectivity. To control for variation between independenttransfections, Env expression was standardized to Gag protein P24
expression in the same cells. The sizes and processing cleavage
efﬁciency of gp160 into gp120 and gp41 were different among tested
env genes. While all Envs showed little size variation in ZM414
(except the prematurely truncated ones), they varied in both ZM400
and ZM413 (Fig. 5). The cleaved gp120 was observed for nearly all
expressed Envs in ZM400, but most were uncleaved gp160 in ZM413
and ZM414. Infectivity of Env pseudoviruses did not to correlate with
the level of Env expression in each individual.
These results suggested that variation in infectivity was not
determined by expression levels or the cleavage efﬁciency of gp160
in transfected cells. It is possible that the amount of Env in transfected
cells was above the threshold required for the production of infectious
pseudoviruses since only a small number of Env spikes are present on
mature HIV-1 particles (Chertova et al., 2002; Zhu et al., 2003). Non-
infectious pseudoviruses were associated with either the absence of
Env expression or with the expression of truncated Envs; these cases
were explained by either premature stop codons or frame-shifting
deletions by sequence analysis.
Autologous and heterologus neutralization
A checkerboard-style dataset of the neutralizing activity in
autologous and heterologous plasma samples was generated by
assaying plasma samples against multiple representative Env-pseu-
dotyped viruses from each subject. Because of the limited supply of
plasma, it was only possible to perform neutralization assays with 60
Env-pseudotyped viruses from 15 subjects (14 subtype C and 1 A/C
recombinant) using plasma samples from these 15 subjects plus one
additional plasma sample (ZM383). Multiple env genes (range 3–6)
from each subject were selected to represent the viral population as
seen in a Maximum likelihood tree analysis (Fig. 6). Three or four env
Table 2
Characterization of clonal expansion env sequences in HIV-1-infected individuals.
ID SGA No. Luciferase
activity
(RLU)
Total viral
population
(%)
No. of amino acid
differences among
env sequences
ZM375 1 434,052 30 3, 4, 5
9 437,851
11 610,112
ZM377 10 175,205 19 1, 2, 3
13 310,710
14 53,926
11 354,745 19 1, 4, 5
12 30,765
16 77,427
ZM378 7 802,968 15 3
9 50,041
ZM394 11 398,245 10 2
18 21,273
ZM395 14 327,566 10 1
15 192,620
ZM401 2 164,195 27 2
19 66,826
20 161,349
ZM402 8 48,981 20 0
12 8,985
ZM405 25 205,738 17 4
44a 1,393
43 92,501 17 0
53 118,441
ZM408 15 118,979 20 3
23a 2,218
ZM411 6 92,343 14 3
9 203,082
ZM413 5 229,782 13 3
13 348,872
ZM414 1 47,219 18 0, 1
10 70,754
23 218,271
28 4,134
9 141,022 14 1
20 240,243
25 126,764
ZM415 1 510,266 16 4
2 114,320
26 553,315
15 496,933 10 1
27 297,937
ZM416 3 391,763 9 2
16 296,184
Control SG3Δenv 1,127
a Stop codon.
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were selected from each lineage in individuals with multiple Env
lineages.
Neutralization results are summarized in Supplementary Table 1. A
majority of virus/plasma combinations (75%) were positive with
neutralization titers of 20–3769, where approximately one-third of
the combinations resulted in a neutralization titer N100. Variable
levels of autologous virus neutralization by contemporaneous plasma
(i.e., plasma obtained at that same time point as Env) were detected in
all but one subject (ZM380). The neutralization potencywas relatively
weak in most cases; however, titers N100 were detected against at
least one variant in the autologous virus quasispecies of 7 subjects
(ZM378, ZM379, ZM401, ZM408, ZM413, ZM416, and ZM417). In
several cases, substantial differences were seen between multiple env
genes from the same subject. For example, titers of autologous
neutralization against multiple env variants ranged from 24 to 598 in
subject ZM408 and from 37 to 449 in subject ZM416.All Env-pseudotyped viruses were then assayed for neutralization
susceptibility by heterologous plasma. Plasma samples were segre-
gated into low (L) and high (H) neutralization potency groups by
heatmap analysis (Fig. 7). Statistically supported clustering of plasma
samples was observed, with the distinctive low-activity cluster boxed
on the left. Overall, seven plasma samples had limited cross-
neutralizing activity. However, the other nine plasma samples
possessed moderate to potent cross-reactive neutralization activity
(Fig. 7 and Supplementary Table 1). Some plasmas (ZM408, ZM378,
ZM395, and ZM379) neutralized nearly all 60 pseudoviruses from the
15 infected individuals.
Neutralization signature analysis
Identiﬁcation of plasma samples with potent and cross-reactive
Nabs prompted us to ask if there were signature sequences present
among the Envs associated with the potent neutralizing activity.
Because each plasma sample represented one value per individual, we
used only the consensus sequence of all variants within an individual
for the signature study, thereby capturing the most common amino
acid in each position. Based on the two distinct clusters shown in the
heatmap (Fig. 7), we scanned each position in the alignment for
amino acids associated with either strong or weak subtype C cross-
reactive neutralization responses using the Maximum likelihood tree
correction method previously described (Bhattacharya et al., 2007).
Because of multiple test issues (a test was done for every site in Env),
we used a q-value to estimate the false discovery rate, based on the
distribution of p-values (Storey and Tibshirani, 2003).
Four signature siteswere identiﬁed: three in gp120 andone in gp41
(Fig. 8). Each site had a p-value of 0.03, but a q-value of 0.27; thus it is
probable that one or more of the signatures identiﬁed were false
positives. Nonetheless, we include them here in a hypothesis-raising
mode because they displayed the strongest trends towards signiﬁ-
cance. Intriguingly, three of the four signature sites were found in the
V4 region (393G, 397G, and 413N). The V4 region, in association with
the C3 alpha-2 helical domain, is thought to contribute to patterns of
neutralization susceptibility in subtype C viruses (Gnanakaran et al.,
2007; Moore et al., 2008; Rong et al., 2007) (Fig. 9). The fourth
signaturewas found at the very end of the gp41 cytoplasmdomain and
consisted of a lysine (L) in position 856. The most intriguing signature
was position 413 N, which is part of a potential N-linked glycosylation
(PNLG) site signature that was independently identiﬁed to be
associated with good serological Nab breadth in a multi-subtype
study of envelopes isolated from individuals who had elicited
particularly potent neutralizing antibodies versus those that had
weak responses (Gnanakaran et al., 2010). Thus, Envs associated with
more cross-reactive Nabs tended to have mutated towards an Asn (N)
in position 413. They also tended to havemutations towards Gly (G) in
positions 393 and 397, although position 397 was in a highly variable
region that is difﬁcult to align with conﬁdence. Interestingly,
autologous neutralizing activity was signiﬁcantly higher
(p=0.0016) in the high neutralization plasma group than in the
low-neutralization plasma group of heterologous neutralization
potencies (Fig. 10). In other words, plasmas that possessed stronger
neutralizing activity against heterologous viruses more potently
neutralized the contemporaneous autologous virus. In addition,
positions 393, 397, and 413 were found to be highly variable within
single individuals, indicative of recurrent immunepressure in different
infections at these sites. Collectively, these data suggest that signature
patterns in the V4 loop are associated with potent and cross-reactive
neutralizing antibodies against subtype C viruses.
Discussion
We characterized multiple HIV-1 env genes in each of 37
individuals using SGA and pPCR methods. Sequence and functional
Fig. 2. Phylogenetic tree analysis of clonal expansion env gene sequences. Midpoint-rooted phylogenetic trees were constructed with all env sequences from each individual who
harbored clonal expansion viruses using the neighbor-joining method and the Kimura two-parameter model. Horizontal branch lengths are drawn to scale (the scale bar represents
0.005 nucleotide substitutions per site); vertical separation is for clarity only. Asterisks indicate bootstrap values in which the cluster to the right is supported in 85% or more
replicates (out of 1000). Sequences with identical or nearly identical sequences are marked with black dots at the tip of the tree branches.
Fig. 3. Infectivity of Env pseudoviruses. The infectivity of 474 pseudoviruses from 37 individuals was determined in TZM-bl cells. The env genes were considered positive when the
luciferase activity RLU values were 10-fold greater than those from SG3Δenv backbone control. The dotted line indicates this cutoff.
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Fig. 4. Correlation between viral load and infectivity of Env pseudoviruses. Geometric
means of the average luciferase activity of multiple Env pseudoviruses from each HIV-
1-infected individual were plotted and analyzed by the Kendall's tau rank correlation
coefﬁcient method.
168 J.L. Kirchherr et al. / Virology 409 (2011) 163–174analysis of the env gene quasispecies in each individual showed
frequent clonal expansions, a trend towards a positive correlation
between viral loads and infectivity of Env pseudoviruses, highly
variable infectivity among env gene quasispecies populations, and,
importantly, signature amino acids in the V4 region of sequences inFig. 5.Western blot analysis of HIV-1 protein expression in transfected cells. The 293T cells
viral proteins were separated on a 4–12% gradient reducing gel, were transferred to nitrocellu
2009) to the Env protein. Viral proteins were visualized with secondary antibodies IRDye
Odyssey Infrared Imaging system. The expression levels of Env proteins are expressed as En
relative light unit (RLU). Asterisks indicate the smaller Envs due to premature stop codonsplasmawith high levels of cross-reactive HIV-1 neutralization activity.
Identiﬁcation of such neutralization signatures may have implications
for the development of effective HIV-1 vaccines.
As expected for chronic HIV-1 infection, a highly divergent viral
quasispecies population was detected in the subjects in this study.
Intra-subject env gene diversity was as high as 8%. Using our recently
established pPCR method, we were able to characterize the pheno-
typic properties of a large number of env genes from each HIV-1-
infected individual by generating pseudoviruses without cloning SGA
PCR products. Analysis of the infectivity of 474 Env pseudoviruses
from 37 individuals revealed that a high percentage (80%) of the env
genes were functional. This is consistent with our previous report
with a smaller number of env genes (Kirchherr et al., 2007), but much
higher than the rate (10%) from env gene populations characterized
by bulk PCR from PBMC (Cham et al., 2006). The different rates were
likely due to differences in methods and sample sources used to
obtain env genes. It is likely that nonfunctional PCR-generated
recombinants were avoided by SGA (Keele et al., 2008; Kirchherr et
al., 2007; Palmer et al., 2005; Salazar-Gonzalez et al., 2008).
Functional analysis showed that the infectivity of Env pseudo-
viruses from the same individuals varied signiﬁcantly (1–2 logs) intransfected with pPCR products and pSG3Δenv were lysed 48 h after transfection. The
lose, andwere reactedwith an HIV-1-positive serum and amousemAb 13D5 (Gao et al.,
800-conjugated goat anti-human and Alexa-Fluor680 goat anti-mouse using a LiCor
v (gp160+gp120):P24 ratios. The infectivity of the each Env pseudovirus is shown as
or non-inframe deletions.
Fig. 6. Maximum likelihood phylogenetic tree of the env sequences. All SGA env sequences from 15 HIV-1-infected individuals were included for analysis. Those used for
neutralization assays are indicated with coloredmarks at the tip of the tree branches. Envelopes were selected to be representative of the diversity in the sample. The sequences from
samples with low diversity (monophyletic) are indicated in black; the sequences from samples with two distinctive phylogenetic clusters are colored so that those from one cluster
are red and those from the other are blue; and sequences that represent recombinants between the two clusters are purple.
169J.L. Kirchherr et al. / Virology 409 (2011) 163–174most individuals. This is similar to plasma-derived env genes from one
individual (Huang et al., 2008) but different from PBMC-derived env
genes, which showed uniform infectivity from the same individual
(Cham et al., 2006). Examination of Env proteins in the transfected
cells showed that the variation of infectivity among Env pseudo-
viruses in each individual was not correlated with in vitro expression
levels. With an intact env open-reading frame, the nonfunctionality of
the env genes may be caused by mutations that affect either
incorporation into virus particles or poor interaction with CD4 and
coreceptors on target cells. Interestingly, a positive correlation trend
was observed between the levels of infectivity of Env pseudoviruses
and viral loads in the donor subjects, suggesting that viruses with
more infectious env genes may lead to a high level of viral loads in
vivo.
Sequence analysis showed that 13 of 37 individuals (35%) carried
one or two clusters of closely related sequences among the
quasispecies viral populations. These sequences, unique to each
individual and conserved within that individual, were identical ornearly identical to each other. Since each sequence was obtained from
independent PCR by SGA, they represent in vivo derived independent
viral genomes. The env sequences related to but beginning to diverge
from the identical or nearly identical sequences, as well as
recombinants between these conserved sets and more diverse viruses
from that individual, indicate that there is clonal expansion of some
viruses in the infected individuals. They generally accounted for 9–
38% of viral population. Clonal expansion of some virus species was
found in different tissues in HIV-1-infected individuals (Bull et al.,
2009). In another study, clonal expansion viruses and other divergent
viruses were found in an infectedmother a day after delivery, but only
viruses identical or highly similar to those clonal expansion viruses
were detected in the infected infant at birth (Verhofstede et al., 2003).
The result from this study strongly suggests that clonal expansion
viruses may play an important role in virus transmission and
pathogenesis. The current study cannot explain the sources for clonal
expansion viruses in plasma. It is possible that they are more ﬁt,
selected by immune responses, or from a reservoir activated by
Fig. 7. Hierarchical clustering of viruses and sera based on neutralization titers. Sera are clustered according to their ability to neutralize. Autologous responses are indicated in black
boxes along the diagonal. The env SGA numbers are colored according to diversity: low diversity (black), two distinct groups (red and blue), and recombinant (purple). For ease of
visualization, the heatmap is organized such that the rows (Env pseudoviruses) are arranged according to individuals rather than hierarchical clustering, where hierarchical
clustering patterns of the Env pseudoviruses are shown as a dendrogram to the right of the ﬁgure. Clustering of high and low-neutralization plasma was statistically supported, with
a probability of 0.96 that the distinctive low-neutralization cluster was robust, using the approximately unbiased multistep–multiscale bootstrap resampling method developed by
Shimodaira (2004). To illustrate this grouping, the columns are presented according to like-responses to the pseudoviruses based on the clustering hierarchy shown at the top of the
ﬁgure. The sets of plasma with low (L) or high (H) Nab titers were grouped. Clustering patterns on the right represent signiﬁcant unbiased multistep–multiscale bootstrap
resampling values 95 or greater.
170 J.L. Kirchherr et al. / Virology 409 (2011) 163–174unknown factors. Since they are genetically different from the viruses
in the major viral population and can recombine with other viruses
(Fig. 2I), they might play a role in evasion of immune responses
elicited by themajority viruses in the population. A longitudinal study
of multiple time point samples will be required to test this hypothesis.
An analysis of checkerboard neutralization data with multiple
representative env genes from each individual using autologous and
heterologous plasma samples enable us to classify neutralization
responses and revealed a signature of four amino acids associated
with potent neutralizing plasmas, three of which were near the base
of the V4 loop. Amino acids found in signature sites are not expected
to be perfectly predictive of a complex state like neutralization
phenotype, but the fact that they are enriched in associationwith such
a phenotype indicates that they are important and likely to berelevant to the state. Glycines associated with signature sites 393 and
397 in the V4 loop of gp120 could impact antibody neutralization in
several ways. Firstly, the loss of electrostatic charge associated with
side chains can perturb antibody binding by modulating the
electrostatic potential of the cognate epitope. Secondly, due to their
lack of side chains, glycines exhibit higher ﬂexibility that might affect
conformational motions in the V4 loop. Flexibility and less charge
repulsion due to glycines at positions 393 and 397 might allow V4 to
sample a wide variety of conformations. In contrast, the signature
413N might play a role by mediating N-linked glycosylation and
potentially inhibiting V4 loop movement by steric hindrance.
Site 413 is proximal to the 17b and CCR5 binding sites and is
adjacent to the proximal binding motif RIKQ (HXB2 residues 419–
422). A recent glycopeptide mass spectroscopy (MS) study found that
Fig. 8. The signature amino acid sequences associated with high levels of neutralization activity in plasma. H represents sequences in the group of plasma samples with high
neutralizing activity against heterologous viruses, whereas L represents sequences that exhibited weak neutralizing activity. Numbers are used to show corresponding locations in
the HXB2 reference strain. Dashes indicate the identical amino acids present in the reference sequence. Periods are used to designate gaps to maintain the alignment. Signature sites
associated with potent neutralization are shown in red. Non-signature amino acids in key positions are shown in blue.
Fig. 9. Crystal structure of ligated gp120 with signature amino acids. The ﬁgure shows
three signature sites, 393 (orange), 397 (magneta), and 413 (red) on a crystal structure
of liganded gp120 (PDB:2B4C) (Huang et al., 2005). The V4 loop and alpha-2 helix are
marked in different colors for clariﬁcation. Positions in C3 that exhibit signiﬁcant
contact with these signature sites on V4 are also marked with the same color as the
signature sites. Three-dimensional images were generated using VMD (Humphrey et
al., 1996). Location of marked sites shown on this B clade template for visualization
does not show any signiﬁcant differences if the recently determined X-ray C clade
gp120 from CAP210 (Diskin et al., 2010) is used as a template. This is expected since
rigorous evaluation of root–mean–square deviation (RMSD) between the CD4-bound
truncated gp120 structures from B and C clades showed that both structures are similar
(RMSD ~ 1.0 , S. Gnanakaran, unpublished analysis).
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HIV-1 envelope, CON-S gp140 (Irungu et al., 2008). Both high-
resolution methods, online high-performance liquid chromatogra-
phy–electrospray ionization mass spectrometry (HPLC/ESI-MS), and
ofﬂine HPLC followed by matrix-assisted laser desorption/ionization
mass spectrometry (MALDI-MS) determined that the potential
glycosylation site 413 is, in fact, glycosylated. It is not clear, however,
how glycosylation at this position is associated with higher levels of
neutralizing antibody titers in vivo. This position is quite variable;
indeed the glycosylation site could be enriched in Envs associated
with potent neutralization activity because it is selected against by a
strong response rather than being required to elicit a strong response.
In a recent study, a neutralization signature was investigated in
subtype C sera using 36 sera against a panel of 5 subtype B and 5
subtype C viruses (Rademeyer et al., 2007). No clear clustering of
serological patterns was found to enable tracking of the signature
patterns. However, a correlation between the V1–V4 loop length and
the cross-subtype neutralizing potential was observed. In the current
study, we did not ﬁnd evidence for such a correlation when
comparing the total V1–V4 lengths or the lengths of V1, V2, and V4
separately of the consensus Env from each individual grouped by the
high- and low-neutralization plasma using a Wilcoxon rank statistic.
However, it could simply be that the number of the samples wasFig. 10. Comparison of autologous neutralizing activity between low and high
heterologous neutralizing plasma samples. Nab titers from low heterologous
neutralization plasmas (n=6) or high heterologous neutralization plasmas (n=9)
were compared. Values at Y-axis are the reciprocal plasma dilutions at which luciferase
activity (RLU) was reduced by 50% relative to virus control wells by autologous plasma.
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samples in the current study were from CHI individuals in whom the
length of variable loops had already become longer during the
evolution of immune evasion.
Previous studies also showed that the alpha-2 helix was under
strong selectionpressure (Gnanakaran et al., 2007) and this regionwas
associated with resistance to autologous neutralization of subtype C
viruses (Rong et al., 2007). The V4 region is downstream from the
alpha-2 helix, and they are structurally close to each other. It was also
found that the C3V4 region is likely responsible for inducing
autologous and heterologous Nabs (Moore et al., 2008). The newly
identiﬁed three signature amino acids were located in the vicinity of
the previously reported region targeted byNabs. These signaturesmay
be responsible for eliciting broader andmore potent Nab responses or
represent the escapemutations from the broadlyNabs against subtype
C viruses through similar pathways. In either case, the data suggest
that signature patterns in the V4 loop are important to consider for the
design of a vaccine that can induce potent andbroadly reactiveNabs, at
least for subtype C, which is the most prevalent HIV-1 subtype in the
world.
Methods and materials
Ampliﬁcation of HIV-1 env genes
Plasma samples were collected from 37 HIV-1-positive individuals
enrolled in a study of contemporary HIV-1 strains in Ndola, Zambia.
The study was approved by the ethics committee of the Tropical
Disease Research Centre, the Duke University Institutional Review
Board, and the National Institutes of Health. No people in this study
were treated with antiretroviral drugs. The homosexual activity was
not reported in the study population. The studied individuals in our
study were most likely infected through heterosexual transmission.
Viral RNAwas extracted from the plasma and reverse transcribed into
cDNA using Superscript III (Invitrogen; Carlsbad, CA). Multiple rev/env
genes from each individual were obtained by using single-genome
ampliﬁcation (SGA), followed by the addition of a CMV promoter to
the 5′ end of the SGA products using pPCR technology as previously
described (Kirchherr et al., 2007).
Single-round infection assay
pPCR products were cotransfected with an env-deﬁcient HIV-1
backbone plasmid (pSG3Δenv) into 293 T cells in a 24-well plate using
FuGENE6 transfection reagent (Roche Diagnostics; Indianapolis, IN).
Brieﬂy, pPCR DNA (150 ng) and pSG3Δenv DNA (150 ng) were mixed
with 1.2 μl of FuGENE6 (FuGENE:DNA ratio at 3 μl:1 μg) in a total
volume of 20 μl with serum-free DMEM, incubated for 30 min and
added to 293 T cells (70% conﬂuence) seeded 1 day earlier at 5×104
per well. Forty-eight hours after transfection, supernatants were
harvested. Equal volumes of pseudovirions were added to TZM-bl
cells with DEAE (5 μg/ml) in a 96-well plate (200 μl). Cultures were
incubated for 48 h at 37 °C with 5% CO2. Supernatants (100 μl) from
infected TZM-bl cells were removed and 100 μl of Bright-Glo
Luciferase Assay substrate with buffer (Promega; Madison, WI) was
added to the cells. Following a 2-min incubation, 100 μl of cell lysates
was added to a solid black 96-well plate. Luminescence wasmeasured
with a Wallac 1420 Multilabel Counter (PerkinElmer: Waltham, MA).
Neutralization assay
HIV-1 neutralization was measured as a reduction in luciferase
activity after a single-round infection of TZM-bl cells, as previously
described (Li et al., 2005, 2006). Equal amounts of pseudovirions (200
TCID50) were used in each reaction. Neutralization titers against
pseudoviruses were determined for 16 plasma samples (15 autolo-gous and 1 heterologous to the tested Env pseudoviruses) and one
HIV-1-positive serum control. An amphotropic murine leukemia Env
pseudovirus was also included as non-speciﬁc neutralization control.Western blot
Forty-eight hours after cotransfection with pPCR products and
pSG3Δenv, 293 T cells were lysed with 250 μl of lysis buffer (50 mM
Tris–HCl, 150 mM NaCl, 20 mM EDTA, 1% Triton-X100, 0.1% SDS,
pH 7.4). Cell lysates were mixed with 6× denaturing sample buffer
(300 mM Tris–HCl pH 6.8, 12 mM EDTA, 12% SDS, 864 mM 2-
mercaptoethanol, 60% glycerol, 0.05% bromophenol blue). Samples
were boiled for 10 min and then loaded on a NuPAGE Novex 4–12%
Bis–Tris gel (Invitrogen; Carlesbad, CA). After the samples were
transferred to a nitrocellulose membrane, the membrane was blocked
in PBS containing 1% casein and 0.01% NaN3 for 1 h. The blot was
reactedwith an HIV-1-positive serum (1:500) and amousemAb 13D5
(1 μg/ml) to the HIV-1 Env protein. Finally, the membrane was
reacted with an IRDye800-conjugated afﬁnity puriﬁed goat anti-
human IgG antibody (Rockland Immunochemicals; Gilbertsville, PA)
and an Alexa-Fluor 680-conjugated goat anti-mouse IgG antibody
(Invitrogen; Carlesbad, CA). Fluorescence was detected, and the
density of Env protein and p24 bands was determined with an
Odyssey Infrared Imaging system (LiCor Biosciences; Lincoln, NE). The
level of Env protein in the transfected cells was expressed as fold
differences over the amount of p24 Gag antigen in the same cells.Sequence analysis
Sequences of SGA env amplicons were obtained by cycle-
sequencing and dye terminator methods with an ABI 3730xl genetic
analyzer (Applied Biosystems; Foster City, CA). Individual sequence
fragments for each env SGA were assembled and edited using the
Sequencher program 4.7 (Gene Codes; Ann Arbor, MI). The env
sequences were aligned using CLUSTAL W (Thompson et al., 1994),
and Genecutter (www.hiv.lanl.gov) for obtaining codon aligned ﬁles
that could be used for signature analysis. Phylogenetic tree was
constructed with complete env gene sequences using the neighbor-
joiningmethod (Saitou and Nei, 1987) and the Kimura two-parameter
model (Kimura, 1980). The reliability of topologies was estimated by
performing bootstrap analysis with 1000 replicates.Hierarchical clustering analysis
The neutralizing potential of plasma (the log reciprocal dilution
ID50 scores) was organized into patterns of similar neutralizing
potency when tested against the panel of envelopes used in this study
using the Los Alamos National Lab web-based heatmap interface
(http://www.hiv.lanl.gov/content/sequence/HEATMAP/heatmap.
html) and the statistical package R (R Development Core Team, 2009).
The test panel of Envs was resampled 10,000 times using a random-
with-replacement bootstrap strategy, and this identiﬁed two robust
and distinctive clusters recurring in 96% of the bootstrap samples: one
group with little cross-neutralizing potential and another group with
the ability to cross-neutralize multiple heterologous C clade viruses
(Shimodaira, 2004). These two groups were used for subsequent
signature analysis. The same strategy was used to identify statistically
robust clusters of the Envs with like-neutralizing susceptibility.
Clusters with high bootstrap values typically only included a few
Envs each, and these Env clusters were typically found within a single
subject. Therefore, we decided to organize Env pseudoviruses by
individual in a heatmap ﬁgure (Fig. 7), while retaining the
information regarding signiﬁcant bootstrap clusters, shown super-
imposed onto the ﬁgure.
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We ﬁrst divided the envelope sequences into the two groups,
based on heatmap clustering patterns that indicated whether they
were derived from an individual with plasma with a cross-reactive
neutralizing proﬁle or a weakly neutralizing proﬁle. Alignments used
for signature analysis were generated with GeneCutter (www.hiv.
lanl.gov) to provide codon-aligned DNA for phylogenetic analysis.
Phylogenetically corrected methods were used to identify all
signature sites. Phylogenetic correction is critical because observed
patterns in data can either result from correlations imposed by the
initial historical emergence of a lineage of viruses (founder effects) or,
in the case of HIV-1, be a consequence of recent biological
interactions. Not accounting for founder effects can lead to erroneous
statistical conclusions (Bhattacharya et al., 2007). The sequence of the
virus depends on its full evolutionary history, while causal correla-
tions are manifest in correlations with recent changes. The separation
of the two effects, i.e., a phylogenetic correction, enables one to
estimate the impact of recent changes on the phenotype. This requires
statistical reconstruction of genealogical relationships between the
viruses and an estimate of ancestral states of the viruses. We
implemented this through maximum likelihood phylogenies and
tested for phenotypic associations with mutational patterns based on
change or stasis in a given amino acid, when compared to the most
recent common ancestor, adapting the phylogenetically corrected
Fisher's Exact Methods ﬁrst developed by Bhattacharya et al. (2007).
We screened themutational pattern of each amino acid found at every
column in the alignment. To correct for multiple tests, we used a q-
value to assess the false discovery rate (Storey and Tibshirani, 2003).
The four strongest associations had a p-value of 0.03 and q-value of
0.27, thus it is likely that at least one of the signatures identiﬁed is a
false positive, and only borderline signiﬁcance was obtained overall.
Consequently, these signatures should be considered in a hypothesis-
raising framework as potentially interesting sites that merit further
investigation.
Nucleotide sequences accession numbers
GenBank accession numbers of the env gene sequences are
GU329048-GU329523.
Supplementary material related to this article can be found online
at doi:10.1016/j.virol.2010.09.031.
Acknowledgments
This work was supported by grants from the National Institutes of
Health/National Institute of Allergy and Infectious Diseases [CIPRA (R03
AI054155) to RMM, HIVRAD PO 1 AI35351, Center for HIV/AIDS Vaccine
Immunology (AI067854), Duke Center for AIDS Research (AI64518)
Molecular Virology Core], the Bill and Melinda Gates Foundation, and a
Los Alamos National Laboratory directed research grant.
References
Bhattacharya, T., Daniels, M., Heckerman, D., Foley, B., Frahm, N., Kadie, C., Carlson, J.,
Yusim, K., McMahon, B., Gaschen, B., Mallal, S., Mullins, J.I., Nickle, D.C., Herbeck, J.,
Rousseau, C., Learn, G.H., Miura, T., Brander, C., Walker, B., Korber, B., 2007. Founder
effects in the assessment of HIV polymorphisms and HLA allele associations.
Science 315, 1583–1586.
Binley, J.M., Wrin, T., Korber, B., Zwick, M.B., Wang, M., Chappey, C., Stiegler, G., Kunert, R.,
Zolla-Pazner, S., Katinger, H., Petropoulos, C.J., Burton, D.R., 2004. Comprehensive
cross-clade neutralization analysis of a panel of anti-human immunodeﬁciency virus
type 1 monoclonal antibodies. J. Virol. 78, 13232–13252.
Binley, J.M., Lybarger, E.A., Crooks, E.T., Seaman, M.S., Gray, E., Davis, K.L., Decker, J.M.,
Wycuff, D., Harris, L., Hawkins, N., Wood, B., Nathe, C., Richman, D., Tomaras, G.D.,
Bibollet-Ruche, F., Robinson, J.E., Morris, L., Shaw, G.M., Monteﬁori, D.C., Mascola, J.R.,
2008. Proﬁling the speciﬁcity of neutralizing antibodies in a large panel of plasmas
from patients chronically infected with human immunodeﬁciency virus type 1
subtypes B and C. J. Virol. 82, 11651–11668.Bull, M.E., Learn, G.H., McElhone, S., Hitti, J., Lockhart, D., Holte, S., Dragavon, J., Coombs,
R.W., Mullins, J.I., Frenkel, L.M., 2009. Monotypic human immunodeﬁciency virus
type 1 genotypes across the uterine cervix and in blood suggest proliferation of
cells with provirus. J. Virol. 83, 6020–6028.
Burton, D.R., Desrosiers, R.C., Doms, R.W., Koff, W.C., Kwong, P.D., Moore, J.P., Nabel, G.J.,
Sodroski, J., Wilson, I.A., Wyatt, R.T., 2004. HIV vaccine design and the neutralizing
antibody problem. Nat. Immunol. 5, 233–236.
Cham, F., Zhang, P.F., Heyndrickx, L., Bouma, P., Zhong, P., Katinger, H., Robinson, J., van
der Groen, G., Quinnan Jr., G.V., 2006. Neutralization and infectivity characteristics
of envelope glycoproteins from human immunodeﬁciency virus type 1 infected
donors whose sera exhibit broadly cross-reactive neutralizing activity. Virology
347, 36–51.
Chertova, E., Bess Jr., J.W., Crise, B.J., Sowder, I.R., Schaden, T.M., Hilburn, J.M., Hoxie, J.A.,
Benveniste, R.E., Lifson, J.D., Henderson, L.E., Arthur, L.O., 2002. Envelope
glycoprotein incorporation, not shedding of surface envelope glycoprotein
(gp120/SU), is the primary determinant of SU content of puriﬁed human
immunodeﬁciency virus type 1 and simian immunodeﬁciency virus. J Virol 76,
5315–5325.
Cordonnier, A., Montagnier, L., Emerman, M., 1989. Single amino-acid changes in HIV
envelope affect viral tropism and receptor binding. Nature 340, 571–574.
Derdeyn, C.A., Decker, J.M., Bibollet-Ruche, F., Mokili, J.L., Muldoon, M., Denham, S.A.,
Heil, M.L., Kasolo, F., Musonda, R., Hahn, B.H., Shaw, G.M., Korber, B.T., Allen, S.,
Hunter, E., 2004. Envelope-constrained neutralization-sensitive HIV-1 after
heterosexual transmission. Science 303, 2019–2022.
Desrosiers, R.C., 2004. Prospects for an AIDS vaccine. Nat. Med. 10, 221–223.
Dhillon, A.K., Donners, H., Pantophlet, R., Johnson,W.E., Decker, J.M., Shaw, G.M., Lee, F.H.,
Richman, D.D., Doms, R.W., Vanham, G., Burton, D.R., 2007. Dissecting the neutralizing
antibody speciﬁcities of broadly neutralizing sera from human immunodeﬁciency
virus type 1-infected donors. J. Virol. 81, 6548–6562.
Diskin, R., Marcovecchio, P.M., Bjorkman, P.J., 2010. Structure of a clade C HIV-1 gp120
bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat.
Struct. Mol. Biol. 17, 608–613.
Fang, G., Zhu, G., Burger, H., Keithly, J.S., Weiser, B., 1998. Minimizing DNA
recombination during long RT-PCR. J. Virol. Meth. 76, 139–148.
Gao, F., Scearce, R.M., Alam, S.M., Hora, B., Xia, S., Hohm, J.E., Parks, R.J., Ogburn, D.F.,
Tomaras, G.D., Park, E., Lomas,W.E., Maino, V.C., Fiscus, S.A., Cohen,M.S., Moody,M.A.,
Hahn, B.H., Korber, B.T., Liao, H.X., Haynes, B.F., 2009. Cross-reactive monoclonal
antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology
394, 91–98.
Gnanakaran, S., Lang, D., Daniels, M., Bhattacharya, T., Derdeyn, C.A., Korber, B., 2007.
Clade-speciﬁc differences between human immunodeﬁciency virus type 1 clades B
and C: diversity and correlations in C3-V4 regions of gp120. J. Virol. 81, 4886–4891.
Gnanakaran, S., Daniels, M.G., Bhattacharya, T., Lapedes, A.S., Sethi, A., Li, M., Tang, H.,
Greene, K., Gao, H., Haynes, B.F., Cohen, M.S., Shaw, G.M., Seaman, M.S., Kumar, A.,
Gao, F., Monteﬁori, D.C., Korber, B., 2010. Genetic signatures in the envelope
glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS
Comput. Biol. 6, e1000955.
Haynes, B.F., Monteﬁori, D.C., 2006. Aiming to induce broadly reactive neutralizing
antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccin. 5, 347–363.
Hemelaar, J., Gouws, E., Ghys, P.D., Osmanov, S., 2006. Global and regional distribution
of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20, W13–W23.
Huang, C.C., Tang, M., Zhang, M.Y., Majeed, S., Montabana, E., Stanﬁeld, R.L., Dimitrov, D.S.,
Korber, B., Sodroski, J., Wilson, I.A., Wyatt, R., Kwong, P.D., 2005. Structure of a V3-
containing HIV-1 gp120 core. Science 310, 1025–1028.
Huang, W., Toma, J., Fransen, S., Stawiski, E., Reeves, J.D., Whitcomb, J.M., Parkin, N.,
Petropoulos, C.J., 2008. Coreceptor tropism can be inﬂuenced by amino acid
substitutions in the gp41 transmembrane subunit of human immunodeﬁciency
virus type 1 envelope protein. J. Virol. 82, 5584–5593.
Humphrey, W., Dalke, A., Schulten, K., 1996. VMD: visual molecular dynamics. J. Mol.
Graph. 14 (33–38), 27–38.
Irungu, J., Go, E.P., Zhang, Y., Dalpathado, D.S., Liao, H.X., Haynes, B.F., Desaire, H., 2008.
Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide
analysis of a highly glycosylated HIV envelope glycoprotein. J. Am. Soc. Mass
Spectrom. 19, 1209–1220.
Kalia, V., Sarkar, S., Gupta, P., Montelaro, R.C., 2005. Antibody neutralization escape
mediated by point mutations in the intracytoplasmic tail of human immunodeﬁ-
ciency virus type 1 gp41. J. Virol. 79, 2097–2107.
Keele, B.F., Giorgi, E.E., Salazar-Gonzalez, J.F., Decker, J.M., Pham, K.T., Salazar, M.G., Sun,
C., Grayson, T., Wang, S., Li, H., Wei, X., Jiang, C., Kirchherr, J.L., Gao, F., Anderson, J.A.,
Ping, L.H., Swanstrom, R., Tomaras, G.D., Blattner, W.A., Goepfert, P.A., Kilby, J.M.,
Saag, M.S., Delwart, E.L., Busch, M.P., Cohen, M.S., Monteﬁori, D.C., Haynes, B.F.,
Gaschen, B., Athreya, G.S., Lee, H.Y., Wood, N., Seoighe, C., Perelson, A.S.,
Bhattacharya, T., Korber, B.T., Hahn, B.H., Shaw, G.M., 2008. Identiﬁcation and
characterization of transmitted and early founder virus envelopes in primary HIV-1
infection. Proc. Natl Acad. Sci. USA 105, 7552–7557.
Kimura, M., 1980. A simple method for estimating evolutionary rates of base
substitutions through comparative studies of nucleotide sequences. J. Mol. Evol.
16, 111–120.
Kirchherr, J.L., Lu, X., Kasongo, W., Chalwe, V., Mwananyanda, L., Musonda, R.M., Xia, S.M.,
Scearce, R.M., Liao, H.X., Monteﬁori, D.C., Haynes, B.F., Gao, F., 2007. High throughput
functional analysis of HIV-1 env genes without cloning. J. Virol. Meth. 143, 104–111.
Korber, B., Gnanakaran, S., 2009. The implications of patterns in HIV diversity for
neutralizing antibody induction and susceptibility. Curr. Opin. HIV AIDS 4,
408–417.
Korber, B.T., Letvin, N.L., Haynes, B.F., 2009. T-cell vaccine strategies for human
immunodeﬁciency virus, the virus with a thousand faces. J. Virol. 83, 8300–8314.
174 J.L. Kirchherr et al. / Virology 409 (2011) 163–174Kulkarni, S.S., Lapedes, A., Tang, H., Gnanakaran, S., Daniels, M.G., Zhang, M.,
Bhattacharya, T., Li, M., Polonis, V.R., McCutchan, F.E., Morris, L., Ellenberger, D.,
Butera, S.T., Bollinger, R.C., Korber, B.T., Paranjape, R.S., Monteﬁori, D.C., 2009.
Highly complex neutralization determinants on a monophyletic lineage of newly
transmitted subtype C HIV-1 Env clones from India. Virology 385, 505–520.
LaBranche, C.C., Sauter, M.M., Haggarty, B.S., Vance, P.J., Romano, J., Hart, T.K., Bugelski,
P.J., Marsh, M., Hoxie, J.A., 1995. A single amino acid change in the cytoplasmic
domain of the simian immunodeﬁciency virus transmembrane molecule increases
envelope glycoprotein expression on infected cells. J. Virol. 69, 5217–5227.
Li, M., Gao, F., Mascola, J.R., Stamatatos, L., Polonis, V.R., Koutsoukos, M., Voss, G.,
Goepfert, P., Gilbert, P., Greene, K.M., Bilska, M., Kothe, D.L., Salazar-Gonzalez, J.F.,
Wei, X., Decker, J.M., Hahn, B.H., Monteﬁori, D.C., 2005. Human immunodeﬁciency
virus type 1 env clones from acute and early subtype B infections for standardized
assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108–10125.
Li, M., Salazar-Gonzalez, J.F., Derdeyn, C.A., Morris, L., Williamson, C., Robinson, J.E.,
Decker, J.M., Li, Y., Salazar, M.G., Polonis, V.R., Mlisana, K., Karim, S.A., Hong, K.,
Greene, K.M., Bilska, M., Zhou, J., Allen, S., Chomba, E., Mulenga, J., Vwalika, C., Gao,
F., Zhang, M., Korber, B.T., Hunter, E., Hahn, B.H., Monteﬁori, D.C., 2006. Genetic and
neutralization properties of subtype C human immunodeﬁciency virus type 1
molecular env clones from acute and early heterosexually acquired infections in
Southern Africa. J. Virol. 80, 11776–11790.
Li, Y., Migueles, S.A., Welcher, B., Svehla, K., Phogat, A., Louder, M.K., Wu, X., Shaw, G.M.,
Connors, M., Wyatt, R.T., Mascola, J.R., 2007. Broad HIV-1 neutralization mediated
by CD4-binding site antibodies. Nat. Med. 13, 1032–1034.
Lin, G., Nara, P.L., 2007. Designing immunogens to elicit broadly neutralizing antibodies
to the HIV-1 envelope glycoprotein. Curr. HIV Res. 5, 514–541.
Liu, S.L., Rodrigo, A.G., Shankarappa, R., Learn, G.H., Hsu, L., Davidov, O., Zhao, L.P.,
Mullins, J.I., 1996. HIV quasispecies and resampling. Science 273, 415–416.
Moore, J.P., McCutchan, F.E., Poon, S.W., Mascola, J., Liu, J., Cao, Y., Ho, D.D., 1994.
Exploration of antigenic variation in gp120 from clades A through F of human
immunodeﬁciency virus type 1 by using monoclonal antibodies. J. Virol. 68,
8350–8364.
Moore, P.L., Gray, E.S., Choge, I.A., Ranchobe, N., Mlisana, K., Abdool Karim, S.S.,
Williamson, C., Morris, L., 2008. The c3-v4 region is a major target of autologous
neutralizing antibodies in human immunodeﬁciency virus type 1 subtype C
infection. J. Virol. 82, 1860–1869.
Moore, P.L., Ranchobe, N., Lambson, B.E., Gray, E.S., Cave, E., Abrahams, M.R., Bandawe,
G., Mlisana, K., Abdool Karim, S.S., Williamson, C., Morris, L., 2009. Limited
neutralizing antibody speciﬁcities drive neutralization escape in early HIV-1
subtype C infection. PLoS Pathog. 5, e1000598.
Morris, J.F., Sternberg, E.J., Gutshall, L., Petteway Jr., S.R., Ivanoff, L.A., 1994. Effect of a
single amino acid substitution in the V3 domain of the human immunodeﬁciency
virus type 1: generation of revertant viruses to overcome defects in infectivity in
speciﬁc cell types. J. Virol. 68, 8380–8385.
Palmer, S., Kearney, M., Maldarelli, F., Halvas, E.K., Bixby, C.J., Bazmi, H., Rock, D., Falloon,
J., Davey Jr., R.T., Dewar, R.L., Metcalf, J.A., Hammer, S., Mellors, J.W., Cofﬁn, J.M.,
2005. Multiple, linked human immunodeﬁciency virus type 1 drug resistance
mutations in treatment-experienced patients are missed by standard genotype
analysis. J. Clin. Microbiol. 43, 406–413.
R Development Core Team, 2009. A Language and Environment for Statistical
Computing. R Foundation for Statistical Computing, Vienna, Austria.
Rademeyer, C., Moore, P.L., Taylor, N., Martin, D.P., Choge, I.A., Gray, E.S., Sheppard, H.
W., Gray, C., Morris, L., Williamson, C., 2007. Genetic characteristics of HIV-1
subtype C envelopes inducing cross-neutralizing antibodies. Virology 368,
172–181.
Rong, R., Gnanakaran, S., Decker, J.M., Bibollet-Ruche, F., Taylor, J., Sfakianos, J.N., Mokili,
J.L., Muldoon, M., Mulenga, J., Allen, S., Hahn, B.H., Shaw, G.M., Blackwell, J.L.,
Korber, B.T., Hunter, E., Derdeyn, C.A., 2007. Unique mutational patterns in the
envelope alpha 2 amphipathic helix and acquisition of length in gp120
hypervariable domains are associated with resistance to autologous neutralization
of subtype C human immunodeﬁciency virus type 1. J. Virol. 81, 5658–5668.
Rong, R., Li, B., Lynch, R.M., Haaland, R.E., Murphy, M.K., Mulenga, J., Allen, S.A., Pinter,
A., Shaw, G.M., Hunter, E., Robinson, J.E., Gnanakaran, S., Derdeyn, C.A., 2009. Escape
from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection
requires multiple pathways. PLoS Pathog. 5, e1000594.
Saitou, N., Nei, M., 1987. The neighbor-joining method: a new method for reconstruct-
ing phylogenetic trees. Mol. Biol. Evol. 4, 406–425.
Salazar-Gonzalez, J.F., Bailes, E., Pham, K.T., Salazar, M.G., Guffey, M.B., Keele, B.F., Derdeyn,
C.A., Farmer, P., Hunter, E., Allen, S., Manigart, O., Mulenga, J., Anderson, J.A.,
Swanstrom, R., Haynes, B.F., Athreya, G.S., Korber, B.T., Sharp, P.M., Shaw, G.M.,
Hahn, B.H., 2008. Deciphering human immunodeﬁciency virus type 1 transmissionand early envelope diversiﬁcation by single-genome ampliﬁcation and sequencing.
J. Virol. 82, 3952–3970.
Sather, D.N., Armann, J., Ching, L.K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X.,
Wood, B., Self, S., Kalams, S., Stamatatos, L., 2009. Factors associated with the
development of cross-reactive neutralizing antibodies during human immunode-
ﬁciency virus type 1 infection. J. Virol. 83, 757–769.
Shen, X., Parks, R.J., Monteﬁori, D.C., Kirchherr, J.L., Keele, B.F., Decker, J.M., Blattner, W.A.,
Gao, F.,Weinhold, K.J., Hicks, C.B., Greenberg,M.L., Hahn, B.H., Shaw, G.M., Haynes, B.F.,
Tomaras, G.D., 2009. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody
epitope mediate human immunodeﬁciency virus type 1 neutralization breadth. J.
Virol. 83, 3617–3625.
Shimizu, N., Haraguchi, Y., Takeuchi, Y., Soda, Y., Kanbe, K., Hoshino, H., 1999. Changes
in and discrepancies between cell tropisms and coreceptor uses of human
immunodeﬁciency virus type 1 induced by single point mutations at the V3 tip
of the env protein. Virology 259, 324–333.
Shimodaira, H., 2004. Approximately unbiased tests of regions using multistep-
multiscale bootstrap resampling. Ann. Stat. 32, 2616–2641.
Shioda, T., Oka, S., Ida, S., Nokihara, K., Toriyoshi, H., Mori, S., Takebe, Y., Kimura, S.,
Shimada, K., Nagai, Y., et al., 1994. A naturally occurring single basic amino acid
substitution in the V3 region of the human immunodeﬁciency virus type 1 env
protein alters the cellular host range and antigenic structure of the virus. J. Virol. 68,
7689–7696.
Stamatatos, L., Morris, L., Burton, D.R., Mascola, J.R., 2009. Neutralizing antibodies
generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat.
Med. 15, 866–870.
Storey, J.D., Tibshirani, R., 2003. Statistical signiﬁcance for genomewide studies. Proc.
Natl Acad. Sci. USA 100, 9440–9445.
Thompson, J.D., Higgins, D.G., Gibson, T.J., 1994. CLUSTAL W: improving the sensitivity
of progressive multiple sequence alignment through sequence weighting, position-
speciﬁc gap penalties and weight matrix choice. Nucleic Acids Res. 22, 4673–4680.
Trkola, A., Pomales, A.B., Yuan, H., Korber, B., Maddon, P.J., Allaway, G.P., Katinger, H.,
Barbas III, C.F., Burton, D.R., Ho, D.D., et al., 1995. Cross-clade neutralization of
primary isolates of human immunodeﬁciency virus type 1 by human monoclonal
antibodies and tetrameric CD4-IgG. J. Virol. 69, 6609–6617.
Verhofstede, C., Demecheleer, E., De Cabooter, N., Gaillard, P., Mwanyumba, F., Claeys,
P., Chohan, V., Mandaliya, K., Temmerman, M., Plum, J., 2003. Diversity of the
human immunodeﬁciency virus type 1 (HIV-1) env sequence after vertical
transmission in mother–child pairs infected with HIV-1 subtype A. J. Virol. 77,
3050–3057.
Walker, L.M., Phogat, S.K., Chan-Hui, P.Y., Wagner, D., Phung, P., Goss, J.L., Wrin, T.,
Simek, M.D., Fling, S., Mitcham, J.L., Lehrman, J.K., Priddy, F.H., Olsen, O.A., Frey, S.M.,
Hammond, P.W., Miiro, G., Serwanga, J., Pozniak, A., McPhee, D., Manigart, O.,
Mwananyanda, L., Karita, E., Inwoley, A., Jaoko, W., Dehovitz, J., Bekker, L.G.,
Pitisuttithum, P., Paris, R., Allen, S., Kaminsky, S., Zamb, T., Moyle, M., Koff, W.C.,
Poignard, P., Burton, D.R., 2009. Broad and potent neutralizing antibodies from an
African donor reveal a New HIV-1 vaccine target. Science 326, 285–289.
Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-Gonzalez, J.F.,
Salazar, M.G., Kilby, J.M., Saag, M.S., Komarova, N.L., Nowak, M.A., Hahn, B.H.,
Kwong, P.D., Shaw, G.M., 2003. Antibody neutralization and escape by HIV-1.
Nature 422, 307–312.
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W.R., Seaman, M.S., Zhou, T., Schmidt,
S.D., Wu, L., Xu, L., Longo, N.S., McKee, K., O'Dell, S., Louder, M.K., Wycuff, D.L., Feng,
Y., Nason, M., Doria-Rose, N., Connors, M., Kwong, P.D., Roederer, M., Wyatt, R.T.,
Nabel, G.J., Mascola, J.R., 2010. Rational design of envelope identiﬁes broadly
neutralizing human monoclonal antibodies to HIV-1. Science 329, 856–861.
Zhang, P.F., Cham, F., Dong, M., Choudhary, A., Bouma, P., Zhang, Z., Shao, Y., Feng, Y.R.,
Wang, L., Mathy, N., Voss, G., Broder, C.C., Quinnan Jr., G.V., 2007. Extensively cross-
reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc.
Natl Acad. Sci. USA 104, 10193–10198.
Zhou, T., Georgiev, I., Wu, X., Yang, Z.Y., Dai, K., Finzi, A., Do Kwon, Y., Scheid, J., Shi, W.,
Xu, L., Yang, Y., Zhu, J., Nussenzweig, M.C., Sodroski, J., Shapiro, L., Nabel, G.J.,
Mascola, J.R., Kwong, P.D., 2010. Structural basis for broad and potent neutraliza-
tion of HIV-1 by antibody VRC01. Science 329, 811–817.
Zhu, P., Chertova, E., Bess Jr., J., Lifson, J.D., Arthur, L.O., Liu, J., Taylor, K.A., Roux, K.H.,
2003. Electron tomography analysis of envelope glycoprotein trimers on HIV and
simian immunodeﬁciency virus virions. Proc. Natl Acad. Sci. USA 100,
15812–15817.
Zwick, M.B., Labrijn, A.F., Wang, M., Spenlehauer, C., Saphire, E.O., Binley, J.M., Moore, J.P.,
Stiegler, G., Katinger, H., Burton, D.R., Parren, P.W., 2001. Broadly neutralizing
antibodies targeted to the membrane-proximal external region of human immuno-
deﬁciency virus type 1 glycoprotein gp41. J. Virol. 75, 10892–10905.
